

ASX ANNOUNCEMENT

CELLMID RECEIVES \$840K R&D TAX CREDIT

SYDNEY, Friday, 27 September 2019: Cellmid Limited (ASX: CDY) advises that it has received \$840K from the Australian Taxation Office under the Research and Development Tax Incentive Scheme for the 2019 financial year.

The tax credit relates to research and development expenditure incurred by the Company in relation to its midkine and FGF5 inhibitor programmes.

End

Contact:

Maria Halasz, CEO

T +612 9221 6830



@mariahalasz

Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences company with a consumer health business and biotech assets. The Company, through its wholly owned subsidiaries, Lyramid and Advangen, develops and markets innovative novel therapies and diagnostic tests for diseases and conditions associated with aging, such as inflammatory diseases, fibrotic diseases, cancer, ischemic diseases of the heart and hair loss. Cellmid holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) and FGF5 globally. Intellectual property pertaining to midkine is being exploited through wholly owned subsidiary Lyramid. Advangen is Cellmid's other wholly owned subsidiary engaged in the development and sale of first in class, best in class, clinically validated anti-aging products for hair, skin and body. Advangen has a range of FGF5 inhibitor hair growth products which are sold in Australia, Japan, USA and China. Advangen has a rich portfolio of hair growth and anti-aging hair care assets which include formulations of products on market, trademarks, patents and patent applications, proprietary assays and manufacturing processes. For further information, please see www.cellmid.com.au and www.evolisproducts.com.au.

Midkine (MK)

Midkine is a growth factor that is highly expressed during embryonic development. Midkine modulates many important biological interactions such as cell growth, cell migration and cellular adherence. These functions are relevant to cancer, inflammation, autoimmunity, ischemia, nerve growth/repair and wound healing. Midkine is barely detectable in healthy adults and only occurs as a consequence of the pathogenesis of a number of different disorders. Cellmid's midkine intellectual property assets are developed by its wholly owned subsidiary, Lyramid Limited.

Forward looking statements

This announcement may have forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially different from the statements in this announcement. Actual results could differ materially depending on factors such as the availability of resources, regulatory environment, the results of marketing and sales activities and competition.